Table 1.

Active clinical trials targeting CAFs in cancers

NCT number	Cancer type	Drug	Compatibe drug		Target/mechanism	Clinical phase	Refs.
NCT02699606	NSCLC, urothelial cancer, gastric cancer, esophageal cancer or cholangiocarcinoma	Erdafitinib		/	A pan- FGFR tyrosine kinase inhibitor	Phase 2	[145]
NCT03762122	Squamous-cell NSCLC	Rogaratinib		/	A pan-FGFR inhibitor	Phase 2	[146]
NCT03386721	Head and neck, oesophageal or cervical cancer	RO6874281		Atezolizumab (MPDL3280A), or Gemcitabine and Vinorelbine	An immunocytokine consisting of IL-2v targeting FAP-α	Phase 2	[147]
NCT02627274	Breast cancer or head and neck cancer	RO6874281		Trastuzumab or Cetuximab	An immunocytokine consisting of IL-2v targeting FAP-α	Phase 1	[148]
NCT03875079	Melanoma	RO6874281		Pembrolizumab	An immunocytokine consisting of IL-2v targeting FAP-α	Phase 1	[149]
NCT03834220	Solid tumors	Debio 1347		/	A pan-FGFR inhibitor	Phase 2	[150]
NCT03822117	Solid tumors	Pemigatinib		/	Targeting activating FGFR mutations or translocations (FIGHT-207)	Phase 2	[151]
NCT02872714	Urothelial cancer	Pemigatinib		/	Tarageting FGF/FGFR alterations (FIGHT-201)	Phase 2	[152]
NCT02924376	Cholangiocarcinoma	Pemigatinib		/	Targeting FGFR2	Phase 2	[153]
NCT02399215	Carcinoid tumor, metastatic carcinoid tumor, or neuroendocrine neoplasm	Nintedanib		/	Blocking VEGFR from attaching to its target	Phase 2	[154]
NCT02834780	Hepatocellular carcinoma	H3B-6527		/	Targeting FGFR4 and FGF19	Phase 1	[155]
NCT03343301	Gastrointestinal cancer	FPA144		mFOLFOX6	Targeting FGFR2	Phase 1	[156]
NCT02432274	Solid malignant tumors or osteosarcoma	Lenvatinib		Ifosfamide, and Etoposide	An inhibitor of VEGFR2 tyrosine kinase with potential antineoplastic activity	Phase 1/2	[157]
NCT02508467	Hepatocellular Carcinoma	Fisogatinib (BLU-554)		/	Targeting FGF19	Phase 1	[158]

FAP fibroblast activation protein; FGF fibroblast growth factor; FGFR fibroblast growth factor receptor; IL-2v interleukin-2 variant; NSCLC non-small-cell lung cancer; VEGFR vascular endothelial growth factor receptor